[go: up one dir, main page]

SV2010003660A - Conjugados antagonistas peptidicos analogos a la bombesina - Google Patents

Conjugados antagonistas peptidicos analogos a la bombesina

Info

Publication number
SV2010003660A
SV2010003660A SV2010003660A SV2010003660A SV2010003660A SV 2010003660 A SV2010003660 A SV 2010003660A SV 2010003660 A SV2010003660 A SV 2010003660A SV 2010003660 A SV2010003660 A SV 2010003660A SV 2010003660 A SV2010003660 A SV 2010003660A
Authority
SV
El Salvador
Prior art keywords
bomb
analogs
peptidic antagonist
antagonist conjugates
peptidic
Prior art date
Application number
SV2010003660A
Other languages
English (en)
Inventor
Helmut Maecke
Jean Claude Reubi
Rosalba Mansi
Original Assignee
Universitaetsspital Basel
Univ Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39677415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2010003660(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universitaetsspital Basel, Univ Bern filed Critical Universitaetsspital Basel
Publication of SV2010003660A publication Critical patent/SV2010003660A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14Peptides being immobilised on, or in, an inorganic carrier
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086Bombesin; Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UN MEDICAMENTO DE DIAGNÓSTICO Y TERAPÉUTICO QUE COMPRENDE UN CONJUGADO ANTAGONISTA PEPTÍDICO ANÁLOGO A LA BOMBESINA QUE TIENE LA FORMULA GENERAL (I), DONDE A ES UN QUELANTE DE METALES QUE COMPRENDE AL MENOS UN RADIONUCLEIDO METÁLICO, B ES UN SEPARADOR UNIDO AL EXTREMO N DE C, O UN ENLACE COVALENTE, Y C ES UN ANTAGONISTA PEPTÍDICO ANÁLOGO A LA BOMBESINA QUE TIENE UNA SECUENCIA COMO LA REIVINDICADA, DONDE ADEMÁS, X ES UN NUMERO ENTERO ENTRE 1 Y 3, Y N ES UN NÚMERO ENTERO ENTRE 1 Y 6(I) [A-(B)N]X-C (FIG. 1)
SV2010003660A 2008-03-07 2010-09-07 Conjugados antagonistas peptidicos analogos a la bombesina SV2010003660A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08075180A EP2100900A1 (en) 2008-03-07 2008-03-07 Bombesin analog peptide antagonist conjugates

Publications (1)

Publication Number Publication Date
SV2010003660A true SV2010003660A (es) 2011-02-17

Family

ID=39677415

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003660A SV2010003660A (es) 2008-03-07 2010-09-07 Conjugados antagonistas peptidicos analogos a la bombesina

Country Status (32)

Country Link
US (2) US9035023B2 (es)
EP (2) EP2100900A1 (es)
JP (1) JP5784911B2 (es)
KR (2) KR101734553B1 (es)
CN (1) CN101965358B (es)
AR (1) AR070809A1 (es)
AU (1) AU2009221204C1 (es)
BR (1) BRPI0909823B1 (es)
CA (1) CA2717427C (es)
CL (1) CL2009000537A1 (es)
CO (1) CO6290707A2 (es)
CR (1) CR11671A (es)
CY (1) CY1118687T1 (es)
DK (1) DK2252628T3 (es)
DO (1) DOP2010000269A (es)
EC (1) ECSP10010467A (es)
ES (1) ES2615805T3 (es)
HU (1) HUE032980T2 (es)
MX (1) MX2010009843A (es)
NZ (1) NZ587795A (es)
PA (1) PA8818501A1 (es)
PE (1) PE20091753A1 (es)
PL (1) PL2252628T3 (es)
PT (1) PT2252628T (es)
RU (1) RU2523531C2 (es)
SI (1) SI2252628T1 (es)
SV (1) SV2010003660A (es)
TW (1) TWI515011B (es)
UA (1) UA103314C2 (es)
UY (1) UY31693A (es)
WO (1) WO2009109332A1 (es)
ZA (1) ZA201006385B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380596A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
EP2380597A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopeptide derivatives and uses thereof
JP2014500262A (ja) * 2010-11-22 2014-01-09 ピラマル イメージング ソシエテ アノニム 放射線治療のための177ルテチウム標識されたボンベシン類似体
EP2710027A1 (en) * 2011-05-19 2014-03-26 Universitätsspital Basel Bombesin receptor targeting peptide incorporating a 1, 2, 3-triazole group in the backbone for preparing in vivo diagnostic and therapeutic agents
HRP20191620T1 (hr) 2012-09-25 2019-12-13 Advanced Accelerator Applications Usa Inc Grpr-antagonisti za otkrivanje, dijagnostiku i liječenje grpr-pozitivnog raka
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
EP2970154B1 (en) * 2013-03-13 2021-07-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications
US20150217006A1 (en) * 2014-02-06 2015-08-06 Immunomedics, Inc. Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
AU2014396468B2 (en) 2014-06-06 2019-02-21 Technische Universitat Munchen Modified cyclopentapeptides and uses thereof
JP7065567B2 (ja) 2014-06-10 2022-05-12 スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ニューロテンシン受容体リガンドを含むコンジュゲートおよびそれらの使用
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP2954934A1 (en) 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
CN106794228B (zh) 2014-06-16 2021-09-03 科德克希思公司 用于治疗麸质不耐受和由其引起的病症的组合物和方法
CN104610431B (zh) * 2014-11-26 2017-12-15 南京市第一医院 一种多肽及其应用
EP3393502A4 (en) 2015-12-16 2019-06-12 Nepetx, LLC COMPOSITIONS AND METHODS OF TREATING GLUTENEAL COMPATIBILITY AND DISORDERS ARISING FROM THE DISEASE
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
US11241511B2 (en) 2016-12-29 2022-02-08 The General Hospital Corporation HER3 peptides for imaging and radiotherapy
ES2960030T3 (es) 2017-01-12 2024-02-29 Radiomedix Inc Tratamiento de células cancerosas que sobreexpresan receptores de somatostatina utilizando derivados de ocreótido quelados con radioisótopos
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
RU2681318C1 (ru) * 2017-11-24 2019-03-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения иммуносупрессорного пептида Abu-TGIRIS-Abu, меченного ионом Gd3+
US20210402016A1 (en) * 2018-11-13 2021-12-30 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CA3145872A1 (en) 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
AU2020405585A1 (en) * 2019-12-19 2022-08-11 Technische Universität München Modified GRPR antagonist peptides for imaging and therapy of cancer
WO2021250240A1 (en) 2020-06-12 2021-12-16 Orano Diaza-18-crown-6 derivative useful for chelating radium, conjugate and radium chelate comprising the same, and uses thereof
EP3973999A1 (en) * 2020-09-28 2022-03-30 Orano Med Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof
WO2022123462A1 (en) 2020-12-09 2022-06-16 3B Pharmaceuticals Gmbh Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CA3242384A1 (en) 2021-12-17 2023-06-22 3B Pharmaceuticals Gmbh Carbonic anhydrase ix ligands
CA3246188A1 (en) 2022-03-25 2023-09-28 The University Of British Columbia Radiolabeled compounds for in vivo imaging of the gastrin-releasing peptide (GRPR) receptor and treatment of GRPR-related disorders
JP2025530229A (ja) 2022-09-07 2025-09-11 3ベー ファーマシューティカルズ ゲーエムベーハー 前立腺特異的膜抗原(psma)リガンドおよびその使用
CN117919452A (zh) * 2023-03-09 2024-04-26 中国科学院宁波材料技术与工程研究所 一种亚细胞器主动靶向成像探针及其制备方法
WO2024212808A1 (zh) * 2023-04-10 2024-10-17 湖南中晟全肽生物科技股份有限公司 蛙皮素类多肽化合物及其用途
EP4455159A1 (en) 2023-04-25 2024-10-30 3B Pharmaceuticals GmbH Gastric inhibitory peptide receptor ligands with bio-distribution modifier
WO2025054727A1 (en) * 2023-09-13 2025-03-20 Provincial Health Services Authority Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
CN120019818A (zh) * 2023-11-20 2025-05-20 湖南中晟全肽生物科技股份有限公司 一种多肽偶联药物及其制备方法和用途
WO2025109003A1 (en) 2023-11-21 2025-05-30 3B Pharmaceuticals Gmbh P-cadherin ligands
WO2025119203A1 (zh) * 2023-12-05 2025-06-12 烟台蓝纳成生物技术有限公司 一种异二聚体放射性核素偶联药物、制备及其应用
US12521455B2 (en) * 2024-04-08 2026-01-13 Radionetics Oncology, Inc. Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5686410A (en) * 1989-07-20 1997-11-11 Novartis Ag Polypeptide derivatives
WO1991001144A1 (en) * 1989-07-20 1991-02-07 Sandoz Ltd Labeled polypeptide derivatives
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
CA2346154A1 (en) 2001-05-02 2002-11-02 University Of Missouri Gastrin receptor-avid peptide conjugates
EP0977579B1 (en) 1997-04-22 2009-03-11 Curator Of The University Of Missouri Gastrin receptor-avid peptide conjugates
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
BR9814484A (pt) 1997-12-24 2000-10-10 Vertex Pharma "pró-drogas de inibidores de aspartil protease"
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
GR1003661B (el) * 2000-05-25 2001-09-05 Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος"... ΣΥΝΘΕΣΗ, ΒΙΟΛΟΓΙΚΗ ΚΑΙ ΠΡΟΚΛΙΝΙΚΗ ΑΞΙΟΛΟΓΗΣΗ ΑΝΑΛΟΓΩΝ ΤΗΣ (D-Phe6, Leu-NHEt13, des-Met14)-ΒΟΜΒΕΣΙΝΗΣ (6-14)ΤΡΟΠΟΠΟΙΗΜΕΝΩΝ ΜΕ ΠΑ ΡΑΓΩΓΑ ΤΟΥ 1,4,8,11-ΤΕΤΡΑΑΖΑΕΝΔΕΚΑΝΙΟΥ(1,4,8,11-TETRAAZAUNDECAN E)ΚΑΙ ΕΠΙΣΗΜΑΣΜΕΝΩΝ ΜΕ ΤΕΧΝΗΤΙΟ-99M- ΓΙΑ ΕΦΑΡΜΟΓΗ ΣΤΗΝ ΟΓΚΟΛΟΓ
CN1461217A (zh) * 2000-12-20 2003-12-10 沃纳-兰伯特公司 非肽铃蟾肽受体拮抗物对治疗焦虑和恐慌紊乱症的新应用
US20080008649A1 (en) 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
KR101106533B1 (ko) * 2003-07-24 2012-01-20 브라코 이미징 에스.피.에이. 안정한 방사성의약 조성물 및 제조 방법
WO2007109475A2 (en) 2006-03-16 2007-09-27 Bracco Imaging S.P.A. Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
JP2014500262A (ja) * 2010-11-22 2014-01-09 ピラマル イメージング ソシエテ アノニム 放射線治療のための177ルテチウム標識されたボンベシン類似体

Also Published As

Publication number Publication date
BRPI0909823A2 (pt) 2019-03-06
CR11671A (es) 2010-11-01
PL2252628T3 (pl) 2017-07-31
HUE032980T2 (en) 2017-11-28
DK2252628T3 (en) 2017-02-06
AU2009221204B2 (en) 2013-09-05
PE20091753A1 (es) 2009-12-13
CY1118687T1 (el) 2017-07-12
PA8818501A1 (es) 2010-04-21
EP2252628A1 (en) 2010-11-24
MX2010009843A (es) 2011-03-04
JP2011515338A (ja) 2011-05-19
EP2252628B1 (en) 2016-12-28
DOP2010000269A (es) 2010-10-31
US9035023B2 (en) 2015-05-19
SI2252628T1 (sl) 2017-05-31
KR101734553B1 (ko) 2017-05-11
PT2252628T (pt) 2017-02-10
TWI515011B (zh) 2016-01-01
CA2717427C (en) 2016-02-23
ES2615805T3 (es) 2017-06-08
EP2100900A1 (en) 2009-09-16
WO2009109332A1 (en) 2009-09-11
CA2717427A1 (en) 2009-09-11
AU2009221204A1 (en) 2009-09-11
US20110097266A1 (en) 2011-04-28
JP5784911B2 (ja) 2015-09-24
ZA201006385B (en) 2016-10-26
CL2009000537A1 (es) 2010-07-19
AR070809A1 (es) 2010-05-05
TW200944239A (en) 2009-11-01
US20150265733A1 (en) 2015-09-24
AU2009221204C1 (en) 2016-12-08
KR20160128425A (ko) 2016-11-07
UA103314C2 (ru) 2013-10-10
NZ587795A (en) 2012-07-27
CO6290707A2 (es) 2011-06-20
RU2010140846A (ru) 2012-04-20
CN101965358B (zh) 2019-09-03
RU2523531C2 (ru) 2014-07-20
UY31693A (es) 2010-01-05
CN101965358A (zh) 2011-02-02
BRPI0909823B1 (pt) 2022-04-19
ECSP10010467A (es) 2010-10-30
KR20110014565A (ko) 2011-02-11

Similar Documents

Publication Publication Date Title
SV2010003660A (es) Conjugados antagonistas peptidicos analogos a la bombesina
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
MX2022006893A (es) Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo.
MX2016010533A (es) Conjugado anticuerpo anti-factor de crecimiento epidermico humano 3 (anti-her3-farmaco).
CR9601A (es) Composiciones y metodos para el tratamiento de sintomas relacionados con el ciclo
CO6362017A2 (es) Peptidos antivirales terapeuticos
CA137511S (en) Display screen
CA138306S (en) Display screen
CA137403S (en) Display screen
SV2001000004A (es) Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
AR070482A1 (es) Montaje para embalaje reforzado
HN2008000792A (es) Compuesto de cinamida biciclico
CL2011002494A1 (es) Compuestos derivados de 7-aza-di-espiro-[3.0.4.1]-decan-8-carboxamida; composición farmacéutica que los comprenden; y uso para el tratamiento de un trastorno asociado con el virus de la hepatitis c (hcv) y el virus de inmunodeficiencia humana (vih).
PA8604401A1 (es) Productos aril-heteroaromaticos, composiciones que los contienen y su utilizacion.
HN2006009000A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
PE20201285A1 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
CO6280503A2 (es) Conjugados de neurturina novedosas para uso farmaceutico
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
BRPI0620229A8 (pt) formulação
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
BRPI0509014A (pt) comprimidos desintegráveis que compreendem licarbazepina
NO20050216L (no) Steroidkonjugater samt fremstilling og anvendelse derav
ES2421938T3 (es) Impulsor para juguete

Legal Events

Date Code Title Description
FD Lapse